Newsletter

Stay up to date on all things ulcers. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Helicobacter Pylori Genome Project

September 9, 2019

Overview

Helicobacter pylori (H. pylori) is a common bacterial infection which can lead to severe stomach problems or stomach cancer. Researchers will be looking at samples of the bacteria taken from chronically infected people in order to identify the genetic differences in H. pylori strains. The findings could help to predict which people with H. pylori will develop cancer, leading to earlier detection and prevention.

 

Study Information

Participants with H. pylori will have 6 small biopsies removed, each one approximately the size of a grain of rice. 

Participants with stomach cancer will donate some of the tissue that will be removed during their clinical care and will allow the study team to access the microscope slides of their stomach.

This is a multi-country, observational study of approximately 2000 people. It began on July 27th 2016 and is estimated to conclude on December 31st 2020.

 

Inclusion Criteria

  1. Adult aged 35 to 70 years old.
  2. Patients who need upper endoscopy (examination of the lining of their stomach with a flexible tube).
  3. Patients recently diagnosed with stomach cancer.

 

Location

There are 57 study locations worldwide. The countries included are: United States, Brazil, Canada, Chile, Colombia, Costa Rica. Egypt, France, Greece, Guatemala, Iceland, India, Iran, Israel, Italy, Japan, Jordan, Kenya, Korea, Kuwait, Latvia, Lithuania, Malaysia, Mexico, Nigeria, Peru, Poland, Portugal, Russia, Spain, Sudan, Sweden, Switzerland, Taiwan, Turkey, Venezuela, Vietnam, Zambia.

 

For more information, please contact Charles S Rabkin, M.D. on (240) 276-7105 or at rabkinc@epndce.nci.nih.gov

 

Sponsors / Collaborators

This study is sponsored by the National Cancer Institute (NCI) with Charles S Rabkin, M.D. as the Principal Investigator.

Clinical Trials

View All Clinical Trials

Multi-Center Acute Severe Ulcerative Colitis Cohort Study

Over one-third of patients with ‘acute severe colitis (ASUC)’ will not respond well to the intravenous…

Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis

T cells are integral to the production and development of ulcerative colitis. GSK2831781 targets these specific T…

Low Sulfur Fecal Transplant for Ulcerative Colitis

It is currently unknown if the microorganisms (microbiota) in patients with ulcerative colitis (UC) is inherently…

Changes Associated With H. Pylori and Gastric Carcinogenesis

This is a research study for patients who currently have or previously had an H. pylori infection or who have…

Benralizumab for Eosinophilic Gastritis

This study seeks to assess the effectiveness of repeat doses of benralizumab to reduce eosinophilic inflammation in…

Outcome Measures in Eosinophilic Gastrointestinal Disorders

The aim of this study is to twofold: firstly, to find the best measures to define how well a person with…

Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers

NuShield® is a dehydrated, sterile placental allograft (donor tissue…

Make a comment and share this article on your profile.

Write a comment for your publication

Successfully Shared!

View on my Profile

Send this to a friend